Is Loading NSTEMI with DAPT Convenient?

Pretreating non-ST elevation acute myocardial infarction (NSTEMI) patients with P2Y12 receptor inhibitors is not associated with improved clinical outcomes as it is to increased bleeding.

doble antiagregación los SCA sin ST

NSTEMI patients are often treated with platelet antiaggregants in the daily clinical practice despite the lack of evidence for its benefits.

This Swedish registry prospectively included 64857 patients undergoing NSTEMI receiving coronary angiography plus angioplasty between 2010 and 2018.

Propensity score matching was used to match patient cohorts between patients pretreated with P2Y12 inhibitors and those who did not.

92.4% of this large cohort of patients received one P2Y12 receptor antagonist, including clopidogrel (43.7%), ticagrelor (54.5%) and prasugrel (1.8%).


Read also: FFR and iFR Discordance in up to 20% of Cases: Which One Should Inform Our Decisions?


Pretreatment was not associated to benefits in terms of 30-day mortality (OR: 1.17; CI 95%, 0.66 to 2.11; p=0.58), mortality at one year (OR: 1.34; CI 95%, 0.77 to 2.34; p=0.30) or stent thrombosis (OR: 0.81; CI 95%, 0.42 to 1.55; p=0.52).

Pretreatment did produce increased in-hospital bleeding in nearly 50% of patients (OR: 1.49; CI 95%, 1.06 to 2.12; p=0.02).

Conclusion

Pretreatment with P2Y12 Receptor Antagonists Preceding Percutaneous Coronary Intervention in Non–ST-Segment Elevation Acute Coronary Syndromes does not bring clinical benefits and increases bleeding. This study strongly recommends against routine pretreatment of these group of patients with P2Y12 receptor antagonists before knowing their anatomy.

dworeck-2020-oi-200664-1600876647-78636-free

Original Title: Association of Pretreatment With P2Y12 Receptor Antagonists Preceding Percutaneous Coronary Intervention in Non–ST-Segment Elevation Acute Coronary Syndromes With Outcomes.

Reference: Christian Dworeck et al. JAMA Network Open. 2020;3(10):e2018735. doi:10.1001/jamanetworkopen.2020.18735.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

TCT 2024 | Use of Drug-Coated Balloons for Side Branch Treatment in Provisional Stenting

In some cases, treating coronary bifurcations with provisional stenting requires side branch stenting, which may lead to suboptimal outcomes. Drug-coated balloons (DCBs) have emerged...

TCT 2024 | Use of Artificial Intelligence for Patients with Suspected Coronary Artery Disease

The current approach to chest pain mainly focuses on symptom characteristics, conducting functional tests for ischemia assessment. However, several randomized clinical trials have shown...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...